Methods for modulating angiogenesis via VEGF
Recombinant plasminogen activator inhibitor-1 (PAI-1) isoforms which lack the reactive center loop and contain the complete heparin-binding domain or lack at least a portion of the heparin-binding domain are described. The rPAI-1 isoforms disclosed herein may be used to modulate angiogenesis through blocking release of VEGF from a VEGF-heparin complex. Furthermore the rPAI-1 proteins may be used to inhibit cell proliferation and migration, induce apoptosis, and produce proteolytic fragments corresponding to angiostatin kringles 1–3 and kringles 1–4.
1. A method of stimulating angiogenesis comprising administering an effective amount of a plasminogen activator inhibitor type 1 isoform lacking a reactive center loop and containing a complete heparin-binding domain so that angiogenesis is stimulated, wherein said plasminogen activator inhibitor type 1 isoform is encoded by nucleotides 390–999 of SEQ ID NO:9 or nucleotides 184–793 of SEQ ID NO:10.